

Bird's foot, Greek hayseed, trigonella, bockshornsame, Methi, hu lu ba
Fenugreek is derived from the dried seeds of the plant and is used traditionally in ayurvedic medicine as a demulcent, laxative, and lactation stimulant. It is also used as a dietary supplement to treat various conditions including diabetes, high cholesterol, wounds, inflammation, and gastrointestinal complaints.
Fenugreek exhibits hypocholesterolemic (1), hypolipidemic (2) (23) and hypoglycemic (3) properties in healthy and diabetic animals and humans. The defatted seed material may reduce gastrointestinal glucose and cholesterol absorption and increase bile acid secretion (4). In addition, fenugreek demonstrated hepatoprotective effects in animals with alcohol-induced liver damage (5) (6).
A few in vitro studies have shown that fenugreek exhibits chemopreventive properties against certain cancers (7) (8) (9) (24). Fenugreek also reduces the toxicity associated with buthionine sulfoximine and cyclophosphamide in mice (25). Human studies have not yet been conducted.
Evidence is limited on fenugreek’s potential as a lactation stimulant. Fenugreek acts as an estrogenic receptor modulator and was shown to stimulate breast cancer cells in vitro (26). Patients with hormonal-sensitive cancers should avoid this product.
Fenugreek exhibits hypocholesterolemic, hypolipidemic, and hypoglycemic activity in healthy and diabetic animals and humans (1) (2). The mechanism is uncertain, but its activity may be associated with the galactomannan fiber and saponin components that reduce gastrointestinal glucose and cholesterol absorption and increase bile acid excretion (14). Hypoglycemic activity is also attributed to the trigonelline, nicotinic acid, and coumarin fractions. 4-Hydroxyisoleucine, an amino acid constituent of fenugreek, potentiates insulin secretion in NIDDM rats when administered intraperitoneally (15). Fenugreek intake in humans is associated with an increase in molar insulin binding sites of erythrocytes, which may enhance glucose utilization (16). In addition to lower fasting and postprandial glucose levels, fenugreek-treated diabetic rats have higher hemoglobin, GSH, and plasma antioxidant levels and lower glycosylated hemoglobin, plasma lipids, and TBARS levels than diabetic controls (4). Dietary fenugreek normalizes the activities of glucose and lipid-metabolizing enzymes in diabetic rats (3). In healthy mice and rats, dietary fenugreek is associated with increased serum T4, liver GSH, glyoxalase I, and GST activities, and decreased T3 levels and T3/T4 ratio (17) (18) (19). Extracts of fenugreek show antimicrobial and nematocidal activity in vitro (20). In MCF-7 estrogen receptor-positive breast cancer cells, fenugreek extract induces cell cycle arrest as well as apoptosis (9).
Fenugreek acts as an estrogenic receptor modulator and was shown to stimulate breast cancer cells in vitro (26). Patients with hormonal-sensitive cancers should avoid this product.
Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood glucose and serum lipids in type I diabetes. Eur J Clin Nutr 1990;44:301-6.
A prospective, controlled crossover evaluation of high-dose dietary fenugreek in 10 insulin-dependent diabetic patients. In two 10-day periods, patients consumed isocaloric diets with or without 100 g defatted fenugreek seed powder in divided doses. Five patients received the fenugreek diet in the first period and the rest received it in the second period. Patients were maintained on suboptimal insulin doses so that the effects of fenugreek could be seen. Oral glucose tolerance tests (administered with insulin) at the end of each study period showed significantly reduced blood glucose levels (p<0.01), but unchanged serum insulin levels. Urinary sugar excretion (p<0.01), serum total cholesterol (p<0.001), VLDL and LDL cholesterol (p<0.01), and triglyceride levels (p<0.01) were also reduced in the fenugreek group.
Bottom Line: Fenugreek may lower blood glucose and cholesterol levels in people with diabetes.
Much research on fenugreek has been conducted in India and other countries, focusing on its potential for the treatment of diabetes. In healthy and diabetic animals and humans, fenugreek lowers cholesterol, blood triglyceride levels, and blood glucose levels. Scientists are not certain how this effect happens, but propose that the fiber in fenugreek binds to glucose and cholesterol in the digestive tract and prevents it from being absorbed by the body, or increases insulin secretion. Laboratory studies in rats show that fenugreek normalizes their blood levels of antioxidants and metabolic enzymes, but it is unclear whether this effect occurs in humans. Fenugreek has anticancer properties but human studies are needed.
Fenugreek acts as an estrogenic receptor modulator and was shown to stimulate breast cancer cells in vitro. Patients with hormonal-sensitive cancers should avoid this product.
Diabetes:
A higher dose of dietary fenugreek was used in a study of ten insulin-dependent diabetic patients. For ten days, patients consumed a planned diet with or without 100 grams of fenugreek seed powder. For another ten days, patients switched to the opposite diet. For the entire time, they were given lower dosages of insulin than usual so that the effects of fenugreek could be seen. After ten days of eating fenugreek, patients had significantly reduced blood glucose levels, urine sugar levels, total cholesterol, LDL (“bad” cholesterol), and triglyceride levels compared to their normal diet levels. Though these results are promising, this study is too small and should be conducted again with more patients.